ArticleOpen life sciences2025
Role of DZ2002 in reducing corneal graft rejection in rats by influencing Th17 activation via inhibition of the PI3K/AKT pathway and downregulation of TRAF1.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the mechanism of DZ2002, a reversible type III S-adenosyl-l-homocysteine hydrolase (SAHH) inhibitor, in alleviating corneal graft rejection in rats through the downregulation of TRAF1 and modulation of Th17 differentiation, so as to provide a new therapeutic strategy for corneal graft rejection. Rat models of corneal graft rejection were constructed and treated with DZ2002 eye drops. Metabolomics and transcriptomics sequencing analyses were used to identify the key metabolite, homocysteine, and its associated gene, TRAF1. Histological assessments were conducted to evaluate the effect of DZ2002 on corneal graft rejection. Additionally, the underlying mechanism of action was explored through Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Homocysteine emerged as a key metabolite involved in corneal graft rejection, and DZ2002 could significantly decrease the rejection index and reduce the opacity and edema of corneal grafts. The effect of DZ2002 in alleviating rejection was attributed to the downregulation of TRAF1 expression, inhibition of the PI3K/AKT pathway, decreased expression of chemokine CCL5 in the aqueous humor, and suppression of the differentiation of T cells into Th17 cells. DZ2002 was effective in reducing corneal graft rejection in rats by downregulating TRAF1 and modulating Th17 differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.